Another meta-analysis of nine studies with 19,660 people with diabetes with COVID-19 suggested that pre-admission use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced mortality (OR 0.53; 95% CI 0.43, 0.66) [18]. This evidence concerns the gene GLP1R and COVID-19.